The XPD Lys751Gln Polymorphism has Predictive Value in Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy: a Systemic Review and Meta-analysis

Qian, Ying-Ying; Liu, Xin-You; Pei, Dong; Xu, Jia-Li; Shen, Hua; Chen, Xiao-Feng; Liu, Yi-Qian; Shen, Li-Zong; Shu, Yong-Qian

추천

검색

자료유형: 학술저널

저자정보: Qian, Ying-Ying (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Liu, Xin-You (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) Pei, Dong (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Xu, Jia-Li (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Shen, Hua (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Chen, Xiao-Feng (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Liu, Yi-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University) Shen, Li-Zong (Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University) Shu, Yong-Qian (Department of Oncology, The First Affiliated Hospital of Nanjing Medical University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제22호

발행연도: 2014.1

수록면: 9,699 - 9,706 (8page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The predictive value of the xeroderma pigmentosum group D (XPD) Lys751Gln polymorphism regarding clinical outcomes of patients with colorectal cancer (CRC) receiving oxaliplatin-based chemotherapy has been evaluated in numerous published studies, but the results remain inconclusive. Therefore, we performed a meta-analysis to determine the precise role of the XPD Lys751Gln polymorphism in this clinical situation and optimize individual chemotherapy. Materials and Methods: A multiple search strategy was used to identify eligible studies. Pooled odds ratios (ORs), generalized odds ratio (ORG) and their 95% confidence intervals (CIs) were used to estimate the objective response, while hazard ratios (HRs) with 95%CIs were used for progression-free survival (PFS) and overall survival (OS). Results: A total of 17 studies including 2,286 patients met the inclusion criteria. Overall, the XPD 751Gln allele was associated with a non-significant reduced objective response to oxaliplatin-based chemotherapy in all patients or in the Asian and Caucasian subgroups. However, poor PFS and OS of CRC patients treated with oxaliplatin-based regimens were significantly related to the XPD 751Gln allele in the dominant model (PFS: HR=2.10, 95%CI: 1.65-2.67; OS: HR=3.18, 95%CI: 1.57-6.47). On stratified analysis by ethnicity, these relationships were more pronounced in Asians (PFS: HR=2.49, 95%CI: 1.79-3.47; OS: HR=5.25, 95%CI: 3.46-7.94) than in Caucasians (PFS: HR=1.73, 95%CI: 1.22-2.46; OS: HR=1.78, 95%CI: 1.06-2.99). Conclusions: The XPD Lys751Gln polymorphism may have prognostic value in patients with CRC undergoing oxaliplatin-based chemotherapy.

#XPD #oxaliplatin #prognosis #chemotherapy #meta-analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요